Montelukast Therapy for Allergic Rhinitis and Asthma

Introduction to Montelukast

The American Academy of Allergy, Asthma, and Immunology recommends montelukast as a safe and effective leukotriene receptor antagonist for both allergic rhinitis and asthma, with particular value in patients who have both conditions or who cannot tolerate intranasal corticosteroids 1, 2

Montelukast produces statistically significant improvement in nasal symptoms and rhinoconjunctivitis quality of life scores compared to placebo in patients with allergic rhinitis 1, 2
The American College of Allergy, Asthma, and Immunology states that montelukast has similar efficacy to oral antihistamines but is less effective than intranasal corticosteroids for allergic rhinitis 1, 3, 4
Combination therapy with an antihistamine provides better symptom control than either therapy alone for allergic rhinitis 1, 2
The American Academy of Family Physicians recommends montelukast as an appropriate alternative therapy for mild persistent asthma in patients unable or unwilling to use inhaled corticosteroids 5, 6

Montelukast is particularly valuable for patients with both allergic rhinitis and asthma, as it can manage both conditions simultaneously 1, 2
The American Academy of Allergy, Asthma, and Immunology suggests that montelukast is a useful option for patients or parents who are "steroid-phobic" 1, 2
Montelukast does not significantly suppress skin tests, which can be advantageous when allergy testing is needed 1, 7

Montelukast is safe for use in children as young as 6 months for perennial allergic rhinitis 1

The American College of Allergy, Asthma, and Immunology states that montelukast plus antihistamine is superior to either alone for allergic rhinitis 1, 2
Intranasal corticosteroids are either equal to or superior to the combination of antihistamine and montelukast for allergic rhinitis 1
The American Academy of Family Physicians recommends that montelukast can be considered as add-on therapy to inhaled corticosteroids for asthma 5, 6

The American College of Allergy, Asthma, and Immunology recommends that intranasal corticosteroids are preferred over montelukast for initial treatment of seasonal allergic rhinitis 3, 4, 8
Patient preference matters, as some patients prefer oral agents like montelukast despite lesser efficacy compared to intranasal corticosteroids 4, 9
The onset of action of montelukast is typically on the second day of treatment, unlike antihistamines which work quickly 1, 7

Adding a daily second‑generation oral antihistamine is recommended to control allergic rhinitis symptoms in patients who are already using inhaled asthma therapy; the antihistamine targets rhinitis specifically and does not interfere with asthma control. 10, 11
The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines state that oral H1‑antihistamines should not be used to treat asthma symptoms themselves, but they are fully appropriate for managing rhinitis in individuals who have both asthma and allergic rhinitis. 10, 11, 12

Inhaled corticosteroids (ICS) are strongly preferred over montelukast as the primary controller medication for asthma, based on moderate‑quality evidence demonstrating superior efficacy. 10, 11, 12
Montelukast becomes a reasonable alternative controller for mild persistent asthma when a patient cannot tolerate or refuses inhaled corticosteroids (e.g., “steroid‑phobic”). 10, 11
If asthma remains inadequately controlled on an adequate dose of inhaled corticosteroids, adding montelukast is an acceptable option; however, long‑acting β‑agonists (LABAs) are generally preferred as the add‑on therapy for patients ≥ 12 years. 11

Step 1 – Optimize inhaled asthma therapy: Ensure the patient is on an appropriate dose of inhaled corticosteroids, with or without a LABA, as the primary asthma controller. 10, 11
Step 4 – Consider montelukast only when:

Montelukast should not be used as the primary asthma controller when inhaled corticosteroids are tolerable; doing so contravenes guideline recommendations and leads to suboptimal asthma control. 10, 11